Last reviewed · How we verify

NCT04513600

ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy

Status unknown Last updated 27 January 2021
What this trial tests

trial testing Cardiac MRI in Transthyretin Amyloidosis in 131 participants. Status unknown.

Timeline
1 August 2020
Primary endpoint
1 August 2022
1 August 2023

Quick facts

Lead sponsorThe Christ Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment131
Start date1 August 2020
Primary completion1 August 2022
Estimated completion1 August 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

The Christ Hospital

Who can join

Adults 18 to 90, any sex, with Transthyretin Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will investigate the stabilization effects of Tafamidis utilizing cardiac imaging cardiac magnetic resonance imaging (CMR). The investigators propose to pursue the following specific aims: 1. Utilize cardiac magnetic resonance to assess stabilization of ATTR after Tafamidis therapy based on extracellular volume mapping. 2. Investigate left ventricular myocardial mass, native T1, T2, and extracellular volume mapping after 12 month follow-up. 3. Utilize cardiac magnetic resonance feature tracking at baseline and at 12 month follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Cardiac MRI

Trials testing the same drug.

Other recruiting trials for Transthyretin Amyloidosis

Currently open trials in the same condition.

Other The Christ Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04513600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing